ZyVersa Therapeutics, Inc. (ZVSA)

US — Healthcare Sector
Peers: CNSP  EFTR  VECT  AVRO  IMMX  HEPA    VIRI  ZURA  NAVB 

Automate Your Wheel Strategy on ZVSA

With Tiblio's Option Bot, you can configure your own wheel strategy including ZVSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZVSA
  • Rev/Share 0.0
  • Book/Share 261.6845
  • PB 0.0025
  • Debt/Equity 0.0
  • CurrentRatio 0.1758
  • ROIC -0.2395

 

  • MktCap 3145230.0
  • FreeCF/Share -156.2248
  • PFCF -0.0006
  • PE -0.0044
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.1193

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
ZVSA
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100.

Read More
image for news ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

About ZyVersa Therapeutics, Inc. (ZVSA)

  • IPO Date 2022-02-11
  • Website https://www.zyversa.com
  • Industry Biotechnology
  • CEO Mr. Stephen C. Glover
  • Employees 7
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.